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ABSTRACT  
 
Objective:  
 
To examine the variation in Long-Acting Reversible Contraceptive (LARC) method 
utilization by women’s source of birth control services.  
 
Design:  
 
Data from the 2011-2013 National Survey of Family Growth was analyzed. The study 
included adult women who received contraceptive services in the past 12 months.  Source 
of contraceptive services was categorized into a) private doctor’s office or HMO facility, 
b) community or public health clinic, c) a family planning or Planned Parenthood clinic 
or d) other source.  Method of contraception was based on women’s reported 
contraceptive use when surveyed and categorized into LARC, high efficacy methods, and 
low efficacy methods, and non-use.  
 
Three multinomial logistic regression models were created to assess the relationship 
between source of services and LARC use, controlling for covariates. The odds of LARC 
use was compared to LARC non-use, high efficacy use and low efficacy use; OR and 
95% confidence intervals were generated.  
 
Results:  
 
There was no statistically significant difference in LARC utilization between women 
receiving services from community or public health clinics and private clinics.  However, 
women receiving care at a family planning clinics had lower odds of LARC use versus 
non-use (OR=0.27, 95% CI=0.10-0.74), versus high efficacy method use (OR=0.32, 95% 
CI=0.11-0.88) and versus low efficacy method use (OR=0.13, 95% CI=0.02-0.87) 
compared to those receiving services at private clinics.  
 
Conclusion: 
 
Women receiving care from family planning clinics had lower odds of LARC use, 
compared to those receiving care from a private doctor’s office or HMO facility. Barriers 
to LARC use should be further investigated. 
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INTRODUCTION 
 Despite advances in contraceptive technology, the rate of unintended pregnancies 
remains high in the United States.  Over half (51%) of all pregnancies in the United 
States are unintentional (Finer and Zolna 2014).  Unintended pregnancies are associated 
with adverse outcomes in both mothers and children (Logan et al. 2007).  For example, 
women with unintended pregnancies initiate prenatal care at a later stage in their 
pregnancy and are less likely to breastfeed their children (D’Angelo et al. 2002).  The 
total public expenditure for unintended pregnancies in the United States was estimated to 
be $21.0 billion in 2010 (Sonfield et al. 2011). 
 Many contraceptive methods are highly effective when couples use them as 
prescribed, both consistently and correctly, but are less effective during typical use 
(Trussell and Wynn 2008).  Oral contraceptive pills (OCPs) are the most commonly used 
reversible contraceptive method in the US (Jones, Mosher, and Daniels 2012), but perfect 
use is dependent upon a strict daily medication regimen.  As such, only 0.3% of women 
experience an unintended pregnancy within a year of perfect use, while 9% of women 
experience an unintended pregnancy within a year of typical use (Hatcher et al. 2011).   
Similarly, women who use contraception consistently account for only 5% of unintended 
pregnancies, even though they make up 68% of the population at risk of pregnancy 
(Sonfield, Hasstedt, and Gold 2014).  
  Long-acting reversible contraception (LARC) methods are among the most 
effective and dependable methods of contraception (Hatcher et al. 2011).  LARC methods 
include both the copper and levonorgestrel intrauterine devices (IUDs), as well as the 
single-rod contraceptive implant.  Not only do these devices have a failure rates of less 
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than 1% (Trussell 2011), but perfect use is not dependent on compliance with a daily 
medication regimen or regular injections from a physician.  As such, the discrepancy in 
failure rates between perfect use and typical use observed among OCP users is not seen 
in LARC users (Trussell 2011).  LARC methods are safe and recommended for use 
among women with comorbidities such as cardiovascular disease and diabetes, as well as 
adolescent and nulliparous women (National Collaborating Centre for Women’s and 
Children’s Health 2005).  Despite the advantages of LARC methods, utilization remains 
relatively low in the United States.  From 2011-2013, only 7.4% of women aged 15-44 
were using LARC methods of contraception (Branum and Jones 2015).  
 Several barriers to LARC use may contribute to low rates of utilization.  Low 
levels of awareness and misperceptions about LARC methods are prevalent.  A telephone 
study of 18- to 30-year-old women in Midwestern states demonstrated low levels of 
awareness of LARC methods, with only 50% of women reporting awareness of IUDs and 
8% reporting awareness of implants (Spies et al. 2010).    
Cost is another barrier to LARC utilization; high out-of-pocket expense is associated with 
failure to obtain an IUD (Gariepy et al. 2011) and the initial cost of a LARC device can 
exceed $800 (Paraguard 2014).  Under the Patient Protection and Affordable Care Act 
(PPACA), LARC methods must be covered without a copay.  However, some insurance 
plans are exempt from this requirement, and many Americans still lack insurance.  
Furthermore, clinicians are the gatekeepers of LARC services.  Not only do clinicians 
provide counseling regarding the appropriateness of a LARC method, but they also 
perform the procedure to implant the devices.  A provider’s knowledge of available 
methods, their training on method delivery, and their beliefs regarding provision of 
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services all impact their patients’ ability to access LARC methods (Luchowski et al. 
2014).  For example, the number of IUDs a physician inserts annually is positively 
correlated with the number of IUDs that they placed in residency and negatively 
correlated with their age (Luchowski et al. 2014).  Different types of health care facilities 
attract different types of providers, with different educational backgrounds, beliefs, and 
experiences, potentially leading to variation in the services delivered to patients.  
OBJECTIVES 
 Studies have shown that reproductive services offered and utilized by women 
differ according to their source of care (Rubin et al. 2015; Frost et al. 2012).  For 
example, at Title-X clinics, women receiving STD services reported that their doctors 
discussed condom use 72% of the time, compared to just 46% of the time at a private 
doctor’s office (Frost 2013).  This study aims to fill a gap in the extant literature by 
determining if LARC utilization varies based on a woman’s source of birth control 
services.  Information regarding the sources of care where LARC methods are 
underutilized could be used in the design of interventions and promotion of LARC use.  
 LARC methods are among the most effective forms of birth control and are 
underutilized in the United States.  LARC methods hold significant promise in preventing 
unintended pregnancies due to imperfect use of contraception.  Theoretically, a woman’s 
odds of receiving a LARC device should only be dependent on her medical needs and 
preferences. Where a woman receives her care should not dictate her ability to access 
these highly effective methods. If variations do occur in rates of LARC use by source of 
care, policy should be crafted to rectify disparities. Similarly if disparities do exist, 
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women should be informed, so they can select a medical provider that best suits their 
contraceptive needs.  
METHODS  
 Data from the 2011-2013 National Survey of Family Growth (NSFG) was 
analyzed.  The NSFG includes detailed information on factors affecting childbearing, 
marriage, and parenthood from a national probability sample of women and men aged 15-
44 (Lepkowski et al. 2010).  Interviews were conducted from September 2011 through 
September 2013.  Black, Hispanic, teenage and female respondents were over sampled 
and sampling weights were used to adjust for the different sampling rates (Lepkowski et 
al. 2010).  The NSFG contained data from 5,601 women, with a 73.4% response rate 
(National Center for Health Statistics 2015).  The data was de-identified and exempted 
from Virginia Commonwealth University IRB approval.   
Adult (age 18 or older) women who received birth control services in the past 12 
months, were not currently pregnant or trying to become pregnant, and were not 
sterilized, nor were their partners sterilized, were included in this analysis. Women who 
had not been sexually active in the past 12 months were excluded.  Women who did not 
know their method of birth control or refused to disclose their method of birth control 
were excluded from the analysis.   
LARC Use 
The outcome variable, LARC use, was determined based on women’s reported 
contraceptive use at the time of the interview.  Birth control use was categorized as: 
LARC users, high efficacy birth control users, low efficacy birth control users or non-
contraceptive users. Women were categorized as LARC users if they utilized a hormonal 
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implant or an IUD, coil, or loop at the time of the interview.  Women were categorized as 
highly effective birth control users if they utilized hormonal methods including Depo-
Provera injections, contraceptive pills, the vaginal ring or transdermal patch.  Low 
efficacy birth control users included those who utilized emergency contraception, the 
male condom, female condom, diaphragm, cervical cap, cream or jelly, suppository, 
withdrawal, natural family planning or another method.  Women who reported receiving 
birth control services, but were not using any form of contraception at the time of the 
interview, were categorized as non-users.  If women reported using multiple methods of 
birth control, they were categorized by their most effective method. 
 The exposure variable, source of care, was categorized into: a) private doctor’s 
office or HMO facility, b) a community or public health clinic, c) a family planning or 
Planned Parenthood Clinic and d) other source of care, including an employer or 
company clinic, a school or school-based clinic, a hospital outpatient clinic, hospital 
emergency room, hospital regular room, urgent care center or some other place.  
 In accordance with previous literature, this study assessed potential confounding 
factors, including socio-demographic factors, life style behaviors, as well as sexual and 
reproductive history (Xu et al. 2011; Kavanaugh et al. 2011; Xu et al. 2012).  The socio-
demographic factors considered include age at interview (18-24, 25-29, 30-24, 35-44), 
race or ethnicity (Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Other, 
Hispanic), whether the individual was born outside of the United States (yes, no), 
relationship status (not married or cohabitating, married, cohabitating), insurance status 
(private insurance, public insurance, other/not covered), poverty status (<100% federal 
poverty level, 100-199%, 200-299%, 300% or higher), educational attainment (no high 
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school diploma or GED, high school diploma or GED, some college, college graduate) 
and region of residence (South, Midwest, Northeast and West).  Sexual and reproductive 
characteristics included number of partners in the past 12 months (1-2 partners, 3 or more 
partners), age at sexual debut (<18 or ≥ 18 years), parity (none, 1 or more births) and if 
the respondent ever discontinued a hormonal birth control method due to dissatisfaction 
(yes, no).  
Descriptive analysis was conducted to examine the characteristics of the study 
population.  A bivariate logistic model was conducted to evaluate the unadjusted 
association between the source of care and method of birth control, as well as the 
unadjusted association between covariates and birth control method.  Three logistic 
models were created:  model one compared the odds of being a LARC user to being a 
non-user (women who received contraceptive services but are using a non-LARC method 
or using no method), the second model compared the odds of being a LARC user versus 
being a highly effective method user and the third model compared the odds of being a 
LARC user versus being a low efficacy method user.   
A multivariate logistic regression model was used to evaluate the association 
between source of birth control services and LARC use, after controlling for confounding 
factors.  Similar to the unadjusted analysis, the association was examined using the three 
models (LARC use compared to non-use, high efficacy method use, and low efficacy 
method use, respectively).  For each model, an iterative process of model building was 
conducted by individually introducing potential confounders into the model.  The 
variables whose inclusion resulted in a greater than 10% change in the odds ratio for 
LARC use were retained in the model.  
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RESULTS 
Table 1 summarizes the socio-demographic, sexual, and reproductive 
characteristics of the study population. The majority of the study population was under 
the age of 30 (69.1%), non-Hispanic white (55.8%), born in the United States (88.1%), 
married or cohabitating (59.8%), covered by private insurance (55.2%), had a college 
degree or some college education (62.4%) and had at least 1 child (57.4%).  The majority 
of the study population used high efficacy contraceptive methods (59.3%), followed by 
LARC use (16.3%).  Low efficacy method users and non-users comprised 11.6% and 
12.8% of the study population, respectively.  Over two-thirds (67.9%) of the women had 
received birth control services from a private doctor’s office or HMO facility. 
Approximately 14%, 12% and 6% of the women reported receiving contraceptive 
services at a community health clinic or public health clinic, family planning or Planned 
Parenthood clinic, or some other location, respectively.   
LARC use versus non-use 
The unadjusted analysis showed a statistically significant association between 
age, relationship status, number of partners, parity, cessation of hormonal method due to 
dissatisfaction, source of care, and LARC use (Table 2).  After adjusting for confounding 
factors, the association between source of care and LARC use remained statistically 
significant (Table 3).  Compared to women receiving care from a private doctor’s office 
or HMO, women receiving care from a family planning or Planned Parenthood clinic had 
lower odds of LARC use (OR=0.27 95% CI=0.10-0.74).   
LARC use versus high-efficacy method use 
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When LARC users were compared to high-efficacy method users, the unadjusted 
analysis showed a statistically significant association between age, relationship status, 
parity, cessation of hormonal method due to dissatisfaction and source of care and LARC 
use (Table 2).  After adjusting for confounding factors, the relationship between source of 
care and LARC use remained significant among women who received care at family 
planning or Planned Parenthood clinics (Table 3).  Compared to women who received 
care from a private doctor’s office or HMO, women who received care from a family 
planning or Planned Parenthood clinic were less likely to use LARC methods as opposed 
to high efficacy methods (OR=0.32 95% CI=0.11-0.88).  No statistically significant 
difference was found in LARC use between women who received care at private doctor’s 
office or HMO facility and those who received care from community health or public 
health clinics.  However, women who received care at other sources, such as hospitals 
and school clinics, had higher odds of using LARC methods versus high efficacy 
methods, compared to those receiving care at private/HMO clinics (OR=4.10 95% 
CI=1.45-11.57). 
LARC use versus low efficacy method use 
When LARC users were compared to low efficacy method users, the unadjusted 
analysis showed a statistically significant association between age, poverty status, source 
of care, and LARC use.  After adjusting for confounding factors, the adjusted analysis 
showed that, compared to women receiving care from a private doctor’s office or HMO, 
women receiving care from a family planning or Planned Parenthood clinic had lower 
odds of LARC use (OR=0.13, 95% CI=0.02-0.87) (Table 3).  No statistically significant 
difference in LARC use was found between women who received care at private doctor’s 
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office or HMO and community or public health clinics or among those who received care 
from other sources.  
DISCUSSION 
 This study found that women who received care from a family planning or 
Planned Parenthood Clinic had lower odds of LARC use compared to women receiving 
care from a private doctor’s office or HMO facility.  On the other hand, women receiving 
contraception services from other sources, such as school clinics and hospitals, showed 
higher odds of using a LARC method as opposed to a high efficacy method. 
 Previous literature exploring the relationship between LARC methods and source 
of care has focused on the availability of contraceptive services by source of care.  
Consistently, literature has shown that clinics with a family planning focus offer a greater 
range of contraceptive services and are more likely to offer LARC methods  (Moskosky 
et al. 2011; Biggs et al. 2014; Frost et al. 2012).  For example, a survey of the medical 
directors of practices participating in California’s family planning Medicaid program 
showed that Planned Parenthood or Community health centers were more likely to 
provide LARC methods on site (Biggs et al. 2014).  Similarly, a national survey of clinics 
providing federally funded contraception services revealed that clinics with a 
reproductive health focus offered a greater range of contraceptive methods and were 
more likely to offer a LARC method (Frost et al. 2012).  Among the surveyed clinics, 
75% of clinics with a reproductive focus offered at least one LARC method, compared to 
just 57% of clinics with a primary care focus (Frost et al. 2012). 
However, few studies have evaluated whether or not the increased availability of 
LARC methods at these facilities translates to higher rates of utilization.  Unlike the 
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findings of the current study, an analysis of California’s family planning Medicaid 
program reported that, compared to those receiving care from a title-X public clinics, 
women who received care from a private provider or non-title X clinic had lower odds of 
LARC method use (Park et al. 2012).  The inconsistent findings between the two studies 
may be explained by the differing study methodology.  While the study in California 
examined the association by title-X status, the current study was not able examine title-X 
status, and instead evaluated LARC utilization by the source of care.   
 Even though family planning clinics are more likely to offer LARC methods to 
patients (Moskosky et al. 2011; Frost et al. 2012), other factors could contribute to low 
rates of utilization.  Staffing differences could be a contributing factor. At publicly 
funded clinics with a family planning focus, method selection counseling is provided by 
health counselors 18% of the time, along with registered nurses (39%), midlevel 
clinicians (30%) , and physicians (5%) (Frost et al. 2012).  However, at publicly funded 
clinics with a primary care focus, health counselors provided contraception method 
selection counseling 8% of the time, along with nurses (22%), midlevel clinicians (41%) , 
and physicians (29%) (Frost et al. 2012).  Providers with less advanced medical training 
may be overly cautious when recommending LARC methods and may have less training 
in the insertion of LARC devices.  A national survey reported that nurse practitioners 
(NPs) frequently use overly restrictive patient eligibility requirements for LARC use, 
inconsistent with CDC guidelines (Harper et al. 2013).  Additionally, only 42% of NPs 
trained in women’s health and 10% of NPs trained in primary care provide long acting 
implants (Harper et al. 2013).   
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 This study sheds some light on the variation in LARC utilization by source of 
birth control services, using a large sample of nationally representative data.  By 
comparing the odds of LARC use to non-use, as well as high efficacy and low efficacy 
method use, these multiple comparisons provide a more robust finding.  Despite its 
strengths, this study is not without limitations.  First, the response variable in this study 
was the contraceptive method at the time of the interview. A woman who used oral 
contraceptive pills for 8 months, but who stopped use in the month of the interview 
would still be documented as a ‘non-user’.  Because the study question was to determine 
LARC use, and LARC varies little month to month, the introduction of bias due to the 
definition may be minimal.  If women ceased LARC use in the month of the interview, 
the estimated rates of use reported in this study may be an underestimate due to the 
misclassification.  
CONCLUSION 
This study shows that women who receive care from a family planning clinic or 
Planned Parenthood clinic are less likely to utilize a LARC method than their peers who 
receive care from a private doctor’s office or HMO.  Although the findings of this study 
were adjusted for socio-demographic factors, family planning clinics predominantly serve 
women who are younger, unmarried, less educated, and from racial or ethnic minorities 
(Frost 2013).  It is possible that young, unmarried and minority women with lower levels 
of education may be disproportionately disadvantaged by low rates of LARC utilization 
at these clinics (Blumenthal, Voedisch, and Gemzell-Danielsson 2010), since higher 
proportion of underserved and minority women receive care from these institutions.   
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Unplanned pregnancy remains a major public health concern in the United States, 
and LARC method utilization shows promise as an effective tool for reducing rates of 
unplanned pregnancy. Given the documented safety and efficacy of LARC methods 
(Stoddard, McNicholas, and Peipert 2011), a 7.4% rate of LARC method use (Branum 
and Jones 2015) represents significant underutilization.  In an analysis of costs 
attributable to unintended pregnancy, 53% of the $4.5 billion dollars in expenditures were 
attributed to imperfect contraceptive adherence (Trussell et al. 2013).  If just 10% of 
women aged 20-29 switched from oral contraception to LARC, total costs would be 
reduced by $288 million per year (Trussell 2007).  Thus, increases in LARC utilization 
could have significant health and financial implications. 
Women who seek care at family planning clinics deserve equal access to the most 
effective forms of birth control.  The barriers that contribute to the lower rates of LARC 
method utilization at family planning and Planned Parenthood clinics are unclear.  Thus, 
further study is necessary to identify the factors that result in low rates of LARC 
utilization by those who seek care at family planning clinics, so that policy remedies can 
be enacted to promote equitable utilization of the most effective methods of birth control.  
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Table 1: Characteristics of women who received Birth Control Services or Prescriptions in the past 12 months, 
2011-2013 National Survey of Family Growth 
!! !! !! !! LARC!non(Users!!
! !
Total!
Population!!
(Weighted!
N!
=7,021,382)!
LARC!Users!
(Weighted!
N=1,143,761)!
All!LARC!non(
users!!
(Weighted!
N=5,877,620)!
High!Efficacy!
Method!User!
(Weighted!
N=4,164,007)!
Low!Efficacy!
Method!User!
(Weighted!
N=815,791)!
Characteristics!! Weighted!Percent!%!
Demographics--
! ! ! ! !Age!! ! ! ! `! ! !
! 18(24! 43.5! 24.4! 47.2! 48.5! 36.1!
!
25(29! 25.6! 33.2! 24.1! 26.2! 16.7!
!
30(34! 17.3! 25.8! 15.7! 11.1! 34.9!
! 35(44! 13.6! 16.6! 13.0! 14.2! 12.4!
Race!or!Ethnicity!! ! ! ! ! !
!
Non(Hispanic!White! 55.8! 58.4! 55.2! 59.8! 42.8!
! Non(Hispanic!Black! 15.1! 11.1! 15.9! 14.6! 19.9!
! Non(Hispanic!Other! 5.2! 3.9! 5.5! 5.8! 7.0!
!
Hispanic! 23.9! 26.5! 23.4! 19.8! 30.2!
Born!outside!of!the!United!States!! ! ! ! ! !
! Yes! 11.9! 20.1! 10.2! 10.3! 14.1!
!
No! 88.1! 79.8! 89.8! 89.7! 85.9!
Relationship!Status!! ! ! ! ! !
! Married!! 36.7! 53.0! 33.5! 35.5! 39.7!
!
Cohabitating!! 23.1! 22.0! 23.3! 21.0! 28.7!
! Not!married!or!cohabitating!! 40.2! 24.9! 43.1! 43.6! 31.6!
Insurance!Status!! ! ! ! ! !
! Private!Insurance! 55.2! 59.5! 54.3! 57.8! 41.9!
!
Public!Insurance!! 28.9! 22.8! 30.1! 28.6! 27.9!
! Other/Not!Covered! 15.9! 17.7! 15.5! 13.6! 30.2!
Poverty!Status!! ! ! ! ! !
!
<100%!of!federal!poverty!level!! 31.4! 28.6! 32.0! 28.8! 50.1!
! 100(199%! 18.9! 19.7! 18.7! 19.0! 11.9!
! 200(299%! 17.1! 16.9! 17.2! 16.9! 16.7!
!
300%!or!higher! 32.6! 34.9! 32.1! 35.3! 21.4!
Education! ! ! ! ! !
! Not!high!school!graduate!! 9.9! 15.3! 8.8! 8.4! 10.0!
!
High!School!or!GED! 27.7! 24.2! 28.4! 25.2! 41.0!
! Some!College! 31.3! 23.8! 32.8! 32.8! 21.5!
! College!Graduate!! 31.1! 36.7! 30.0! 33.7! 27.5!
Region!! ! ! ! ! ! !
!
Northeast! 15.1! 13.6! 15.3! 14.2! 12.1!
! Midwest!! 22.5! 20.7! 22.8! 23.9! 19.3!
! South!! 29.3! 28.4! 29.5! 29.7! 32.0!
!
West!! 33.2! 37.3! 32.4! 32.2! 36.5!
Sexual-and-Reproductive-Characteristics-- ! ! ! ! !
Number!of!Partners!in!Past!12!months!! ! ! ! ! !
!
1(2!Partners!! 90.7! 95.0! 89.8! 91.3! 91.5!
! 3!or!more!Partners!! 9.3! 5.0! 10.2! 8.7! 8.5!
Age!at!first!intercourse!<18! ! ! ! ! !
!
Yes!! 65.1! 63.9! 65.4! 64.9! 56.2!
! No!! 34.9! 36.1! 34.6! 35.1! 43.8!
Total!number!of!live!births!! ! ! ! ! !
!
0! 42.6! 22.0! 46.6! 50.5! 34.1!
!
1!or!more!! 57.4! 78.0! 53.4! 49.5! 65.9!
Ever!stopped!using!a!hormonal!method!due!to!dissatisfaction! ! ! ! ! !
! Yes!! 43.7! 64.5! 39.6! 33.7! 52.4!
!
No!! 56.3! 35.5! 60.4! 66.3! 47.6!
Source!of!Birth!Control!Prescription/Service! ! ! ! ! !
! Private!Doctor's!Office!or!HMO!facility! 67.9! 77.8! 66.0! 68.3! 60.5!
!
Community!Health!Clinic!/!Public!Health!Clinic! 14.0! 9.3! 15.0! 15.1! 11.3!
! Family!Planning!or!Planned!Parenthood!Clinic! 12.0! 4.1! 13.5! 11.5! 21.9!
! Other!! 6.1! 8.8! 5.5! 5.2! 6.4!Method!Currently!Utilized!!
! ! ! ! !
! LARC! 16.3! 100.0! 0.0! 0.0! 0.0!
! High!Efficacy!! 59.3! 0.0! 70.8! 100.0! 0.0!
!
Low!Efficacy! 11.6! 0.0! 13.9! 0.0! 100.0!
!! No!Method!! 12.8! 0.0! 15.3! 0.0! 0.0!
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Table 2: Factors Associated with LARC Use, 2011-2013 National Survey of Family Growth ##
Characteristic**
Weighted*
Percent*
LARC*users*
LARC*use*vs*LARC*
non6use*(Weighted*
N*=7,021,382)*
LARC*use*vs*High*
Efficacy*Use*
(Weighted*
N=5,307,768)*
LARC*use*vs*Low*
Efficacy*Use*
(Weighted*
N=1,959,552)*
* * *
Crude*Odds*Ratio*(95%*Confidence*Interval)*
Age*(Ref*=*18624)* *
* ** 25629* 21.1* 2.67*(1.56,*4.56)** 2.53*(1.44,*4.45)*** 2.95*(1.16,*7.49)**
* 30634* 24.3* 3.19*(1.55,*6.58)** 4.64*(2.42,*8.89)*** 1.10*(0.33,*3.64)**
* 35644* 19.9* 2.48*(0.92,*6.69)* 2.33*(0.84,*6.46)** 1.99*(0.53,*7.48)*
Race*or*Ethnicity*(Ref*=*White)*
* * * ** Non6Hispanic*Black* 12.0* 0.66*(0.35,*1.26)* 0.78*(0.38,*1.64)* 0.41*(0.14,*1.21)*
* Non6Hispanic*Other* 12.2* 0.68*(0.23,*2.01)* 0.69*(0.29,*1.64)** 0.41*(0.04,*4.24)*
* Hispanic* 18.1* 1.07*(0.56,*2.06)* 1.37*(0.64,*2.92)** 0.64*(0.25,*1.67)*
Born*Outside*of*the*United*States*(Ref*=*No)** 27.7* 2.22*(0.91,*5.38)* 2.21*(0.86,*5.68)* 1.55*(0.61,*3.92)*
Relationship*Status*(Ref*=*Not*married/cohabitating)**
* * * ** Married* 23.5* 2.74*(1.37,*5.47)** 2.62*(1.27,*5.37)** 1.69*(0.69,*4.14)*
* Cohabitating** 15.5* 1.63*(0.85,*3.15)** 1.84*(0.95,*3.57)* 0.97*(0.33,*2.90)*
Insurance*Status*(Ref=Not*Covered)*
* * * ** Private*Insurance* 17.6* 0.96*(0.50,*1.83)* 0.79*(0.41,*1.51)* 2.41*(0.87,*6.71)*
* Public*Insurance* 12.8* 0.66*(0.35,*1.24)** 0.61*(0.29,*1.26)* 1.39*(0.58,*3.37)**
Poverty*Status*(Ref=<100%*of*federal*poverty*level*)*
* * * ** 100%6199%*of*FPL* 17.0* 1.18*(0.50,*2.75)* 1.04*(0.44,*2.49)* 2.90*(0.96,*8.74)*
* 2006299%*of*FPL* 16.1* 1.10*(0.47,*2.59)* 1.01*(0.41,*2.48)* 1.78*(0.54,*5.82)*
* 300%*or*higher* 17.4* 1.22*(0.55,*2.67)* 1.00*(0.44,*2.28)* 2.86*(1.02,*8.01)**
Education*(Ref=Not*high*school*graduate)*
* * * ** High*School*or*GED* 14.2* 0.49*(0.15,*1.63)* 0.53*(0.15,*1.90)* 0.38*(0.09,*1.65)*
* Some*College* 12.4* 0.42*(0.13,*1.35)* 0.40*(0.12,*1.35)* 0.72*(0.18,*2.83)**
* College*Graduate** 19.2* 0.70*(0.22,*2.30)* 0.59*(0.17,*2.11)* 0.87*(0.19,*3.92)*
Region*(ref='South')*
* * * *
*
Northeast* 14.7* 0.92*(0.41,*2.09)* 1.01*(0.44,*2.29)* 1.27*(0.35,*4.56)*
*
Midwest* 15.0* 0.94*(0.54,*1.65)* 0.91*(0.49,*1.68)* 1.21*(0.30,*4.82)*
*
West* 18.3* 1.20*(0.56,*2.59)* 1.21*(0.53,*2.80)* 1.15*(0.49,*2.70)*
3*or*more*partners*in*the*past*12*months*(ref=162*partners)* 8.7* 0.46*(0.22,*0.97)** 0.55*(0.25,*1.22)** 0.56*(0.17,*1.83)*
Age*at*first*intercourse*<18**(Ref=18*or*older)* 16.0* 0.94*(0.53,*1.67)* 0.96*(0.53,*1.73)** 1.38*(0.63,*3.00)*
1*or*more*live*births*(ref=no*live*births)* 22.1* 3.09*(1.60,*5.95)** 3.81*(1.99,*7.29)*** 1.83*(0.77,*4.37)*
Stopped*using*hormonal*method*due*to*dissatisfaction*(Ref=No)* 24.0* 2.76*(1.57,*4.88)** 3.57*(1.94,*6.58)*** 1.65*(0.72,*3.75)*
Source*of*Birth*Control*Prescription/Service*(Reference*Private*Doctor's*Office*or*HMO*Facility)*
* * * ** Community*Health*Clinic*/*Public*Health*Clinic* 10.8* 0.53*(0.22,*1.28)* 0.54*(0.21,*1.38)* 0.64*(0.29,*1.43)*
* Family*Planning*or*Planned*Parenthood*Clinic** 5.5* 0.26*(0.10,*0.64)** 0.31*(0.13,*0.77)** 0.15*(0.04,*0.58)**
* Other** 23.7* 1.35*(0.61,*3.03)** 1.50*(0.66,*3.39)* 1.07*(0.21,*5.36)*
**p<0.05****p<0.0001*
 
18##
Table 3: Multivariate Logistic Regression Model 
 
Characteristic** LARC*use**vs.*LARC*non6Use**
(Weighted*N*=7,021,382)*†*
LARC*use*vs.*High*Efficacy*Use*
(Weighted*N=5,307,768)**‡*
LARC*use*vs*Low*Efficacy*Use*
(Weighted*N=1,959,552)**§*
* *
Adjusted*OR*(95%*CI)*
Source*of*Birth*Control*Prescription/Service*(Reference*Private*Doctor's*Office*or*HMO*
Facility)*
* * *
*
Community*Health*Clinic*/*Public*Health*Clinic* 0.47*(0.20,*1.08)* 0.47*(0.19,*1.16)* 0.33*(0.09,*1.27)*
*
Family*Planning*or*Planned*Parenthood*Clinic** 0.27*(0.10,*0.74)** 0.32*(0.11,*0.88)** 0.13*(0.02,*0.87)**
*
Other** 2.22*(0.77,*6.35)* 4.10*(1.45,*11.57)** 1.81*(0.10,*33.69)*
*p<0.05****p<0.0001*
†Other*variables*in*this*multivariate*model*include*age,*race*or*ethnicity,*born*outside*of*the*US,*marital*status*and*parity**
‡Other*variables*in*this*multivariate*model*include*age,*race*or*ethnicity,*born*outside*of*the*US,*marital*status,*education,*number*of*partners*and*parity**
§Other*variables*in*this*multivariate*model*include*age,*race*or*ethnicity,*born*outside*of*the*US,*insurance*status,*education,*region*and*parity**
 
